Skip to content

Study · Non-randomized trial · n = 13 · 2014

6 results

[Three-year follow-up of 12 patients with prostate cancer treated with monthly degarelix in a phase II clinical trial].

Hoshi S, Hayashi N, Yagi M, Ookubo T, Muto A, Sugano O, Numahata K, Bilim V, Hoshi K, Sasagawa I

Gan to kagaku ryoho. Cancer & chemotherapy1 Jan 2014

PMID24423954 (opens in a new tab)PepBankPUB-24423954
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients treated with monthly degarelix, PSA declined in all patients.

    In plain wordsIn prostate cancer patients treated with monthly degarelix, PSA declined from baseline in all patients.

    Peptide
    Degarelix
    Outcome
    DecreasePSA decline
    Study

    n = 13

    Outcome group
    Tumor growth · Cancer
    Studied dose
    80 or 160 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The PSA level declined in all patients.
    2 context sentences
    Summary · context
    The efficacy and safety of degarelix, a luteinizing hormone-releasing hormone(LH-RH)antagonist, in patients with prostate cancer(PCa)were evaluated in a phase II, open-label, multicenter clinical trial.
    Summary · context
    In this trial, a total of 13 patients were accrued at the Yamagata Prefectural Central Hospital from 2007 to 2008.
  2. 02HumanNon-randomized trialSafety outcome

    In the prostate cancer degarelix trial, one patient died of an unrelated cause.

    In plain wordsIn the prostate cancer degarelix trial, one patient died of an unrelated cause.

    Peptide
    Degarelix
    Outcome
    Not applicableDeath during trial
    Study

    n = 13

    Outcome group
    Mortality · Whole body
    Studied dose
    80 or 160 mg monthly · 12 monthsAs given in this study (human).

    Measurements

    Deaths
    1 patients
    unrelated cause during phase II trial

    Source sentences

    Summary
    One patient died of an unrelated cause during the phase II trial.
    2 context sentences
    Summary · context
    The efficacy and safety of degarelix, a luteinizing hormone-releasing hormone(LH-RH)antagonist, in patients with prostate cancer(PCa)were evaluated in a phase II, open-label, multicenter clinical trial.
    Summary · context
    In this trial, a total of 13 patients were accrued at the Yamagata Prefectural Central Hospital from 2007 to 2008.
  3. 03HumanNon-randomized trialEfficacy outcome

    In one patient with cT3aN1M0 prostate cancer, PSA declined to <0.02 ng/mL after degarelix.

    In plain wordsIn one prostate cancer patient, PSA declined to <0.02 ng/mL after degarelix.

    Peptide
    Degarelix
    Outcome
    DecreasePSA response in prolonged responder
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer
    Studied dose
    80 or 160 mg monthly · 12 monthsAs given in this study (human).

    Measurements

    PSA level
    < 0.02 ng/mL
    one patient with cT3aN1M0 PCa

    Source sentences

    Summary
    In 1 patient with cT3aN1M0 PCa, the PSA level declined to <0.02 ng/mL, and a reduction in size of the prostate gland and metastatic lymph nodes was observed.
    3 context sentences
    Summary · context
    This effect persisted for 3.5 years after the completion of the 12-month degarelix regimen, and no additional treatment was required.
    Summary · context
    The efficacy and safety of degarelix, a luteinizing hormone-releasing hormone(LH-RH)antagonist, in patients with prostate cancer(PCa)were evaluated in a phase II, open-label, multicenter clinical trial.
    Summary · context
    In this trial, a total of 13 patients were accrued at the Yamagata Prefectural Central Hospital from 2007 to 2008.
  4. 04HumanNon-randomized trialEfficacy outcome

    In one patient with cT3aN1M0 prostate cancer, prostate gland size decreased after degarelix.

    In plain wordsIn one prostate cancer patient, prostate gland size decreased after degarelix.

    Peptide
    Degarelix
    Outcome
    DecreaseProstate gland size in prolonged responder
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer
    Studied dose
    80 or 160 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In 1 patient with cT3aN1M0 PCa, the PSA level declined to <0.02 ng/mL, and a reduction in size of the prostate gland and metastatic lymph nodes was observed.
    3 context sentences
    Summary · context
    This effect persisted for 3.5 years after the completion of the 12-month degarelix regimen, and no additional treatment was required.
    Summary · context
    The efficacy and safety of degarelix, a luteinizing hormone-releasing hormone(LH-RH)antagonist, in patients with prostate cancer(PCa)were evaluated in a phase II, open-label, multicenter clinical trial.
    Summary · context
    In this trial, a total of 13 patients were accrued at the Yamagata Prefectural Central Hospital from 2007 to 2008.
  5. 05HumanNon-randomized trialEfficacy outcome

    In one patient with cT3aN1M0 prostate cancer, metastatic lymph node size decreased after degarelix.

    In plain wordsIn one prostate cancer patient, metastatic lymph node size decreased after degarelix.

    Peptide
    Degarelix
    Outcome
    DecreaseMetastatic lymph node size in prolonged responder
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer
    Studied dose
    80 or 160 mg monthly · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In 1 patient with cT3aN1M0 PCa, the PSA level declined to <0.02 ng/mL, and a reduction in size of the prostate gland and metastatic lymph nodes was observed.
    3 context sentences
    Summary · context
    This effect persisted for 3.5 years after the completion of the 12-month degarelix regimen, and no additional treatment was required.
    Summary · context
    The efficacy and safety of degarelix, a luteinizing hormone-releasing hormone(LH-RH)antagonist, in patients with prostate cancer(PCa)were evaluated in a phase II, open-label, multicenter clinical trial.
    Summary · context
    In this trial, a total of 13 patients were accrued at the Yamagata Prefectural Central Hospital from 2007 to 2008.
  6. 06HumanNon-randomized trialEfficacy outcome

    In one prostate cancer patient, the response persisted for 3.5 years after completing 12 months of degarelix without additional treatment.

    In plain wordsIn one prostate cancer patient, the response persisted for 3.5 years after degarelix ended without additional treatment.

    Peptide
    Degarelix
    Outcome
    Not applicablePersistence without additional treatment
    Study

    n = 1

    Outcome group
    Tumor growth · Cancer
    Studied dose
    80 or 160 mg monthly · 12 monthsAs given in this study (human).

    Measurements

    Persistence after 12-month degarelix regimen
    3.5 years
    one patient with cT3aN1M0 PCa

    Source sentences

    Summary
    This effect persisted for 3.5 years after the completion of the 12-month degarelix regimen, and no additional treatment was required.
    3 context sentences
    Summary · context
    In 1 patient with cT3aN1M0 PCa, the PSA level declined to <0.02 ng/mL, and a reduction in size of the prostate gland and metastatic lymph nodes was observed.
    Summary · context
    The efficacy and safety of degarelix, a luteinizing hormone-releasing hormone(LH-RH)antagonist, in patients with prostate cancer(PCa)were evaluated in a phase II, open-label, multicenter clinical trial.
    Summary · context
    In this trial, a total of 13 patients were accrued at the Yamagata Prefectural Central Hospital from 2007 to 2008.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.